由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
_pennystock版 - Biotech Calendar: Key Dates for February
相关主题
【Biotech Event Thread】2009 OctBiotech Calendar: 2011-12 FDA Drug Approvals
生拉AVNRWatch GENZ, SNY approach GENZ for interest of buy out
大家看看这几个公司被买断的可能性怎么样? (转载)Sanofi makes $18.5 billion all-cash offer for Genzyme
Stock Lists on Finviz (转载)中国数据强劲,美股期指劲扬
关于医药股操作,再胡说几句 (转载)谨慎推荐 ALIM
说几个最近(一周到半年)有可能有动作的biotech:ALIM的申请 FDA 什么时候 做DECISION?
Biotech Calendar: 2011 FDA Drug ApprovalsNND, 不该涨的都涨了, 该涨的不涨
肝病生拉月末有event | ANDS| IDIXALIM的新药申请 FDA接收了吗?
相关话题的讨论汇总
话题: feb话题: earnings话题: february话题: avnr
1 (共1页)
f**********g
发帖数: 2252
1
http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioTherapeutics Inc.| PLX UPFeb 1:
Discovery Labs(DSCO_): Surfaxin regulatory update conference call.
Earnings: Biogen Idec(BIIB_), Pfizer(PFE_).
Feb. 2
Earnings: Sangamo BioSciences(SGMO_), Viropharma(VPHM_).
Feb 3:
Alimera Sciences(ALIM_): 36-month results from phase III study of Iluvien in
diabetic macular edema.
Earnings: Alkermes(ALKS_), GlaxoSmithKline(GSK_), Avanir Pharmaceuticals(
AVNR_), Merck(MRK_), Vertex Pharmaceuticals(VRTX_),
Feb. 8:
Adeona Pharmaceuticals(AEN_) investor/analyst day.
Earnings: Seattle Genetics(SGEN_), Rigel Pharmaceuticals(RIGL_), Teva(TEVA_)
,
Feb. 9:
Earnings: Sanofi-Aventis(SNY_)
Feb. 10:
Earnings: Alexion Pharmaceuticals(ALXN_), Cephalon(CEPH_), Incyte
Pharmaceuticals(INCY_), MannKind(MNKD_), Momenta Pharmaceuticals(NNTA).
Feb 14-15:
BIO CEO & Investor Conference, New York City.
Feb 15:
Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme(GENZ_).
Feb. 16:
Earnings: Genzyme
Feb. 17:
Exelixis(EXEL_): Presentation of updated cabozantinib (XL184) data in
prostate cancer at ASCO GU symposium
Earnings: Biomarin Pharmaceuticals(BMRN_), Acorda Therapeutics(ACOR_)
Feb. 22:
Earnings: Questcor Pharmaceuticals(QCOR_)
Feb 25:
Pfizer and Protalix Therapeutics(PLX_): FDA approval decision date for
Uplyso in Gaucher's disease.
Other potential February events
Idenix Pharmaceuticals(IDIX_): FDA decision on lifting clinical hold on
hepatitis C drugs IDX184 and IDX320.
Amylin Pharmaceuticals(AMLN_), Alkermes, Eli Lilly(LLY_): Start of a
Bydureon Qt study.
Source: Company reports, BioMedTracker.com
f**********g
发帖数: 2252
2
http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioTherapeutics Inc.| PLX UPFeb 1:
Discovery Labs(DSCO_): Surfaxin regulatory update conference call.
Earnings: Biogen Idec(BIIB_), Pfizer(PFE_).
Feb. 2
Earnings: Sangamo BioSciences(SGMO_), Viropharma(VPHM_).
Feb 3:
Alimera Sciences(ALIM_): 36-month results from phase III study of Iluvien in
diabetic macular edema.
Earnings: Alkermes(ALKS_), GlaxoSmithKline(GSK_), Avanir Pharmaceuticals(
AVNR_), Merck(MRK_), Vertex Pharmaceuticals(VRTX_),
Feb. 8:
Adeona Pharmaceuticals(AEN_) investor/analyst day.
Earnings: Seattle Genetics(SGEN_), Rigel Pharmaceuticals(RIGL_), Teva(TEVA_)
,
Feb. 9:
Earnings: Sanofi-Aventis(SNY_)
Feb. 10:
Earnings: Alexion Pharmaceuticals(ALXN_), Cephalon(CEPH_), Incyte
Pharmaceuticals(INCY_), MannKind(MNKD_), Momenta Pharmaceuticals(NNTA).
Feb 14-15:
BIO CEO & Investor Conference, New York City.
Feb 15:
Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme(GENZ_).
Feb. 16:
Earnings: Genzyme
Feb. 17:
Exelixis(EXEL_): Presentation of updated cabozantinib (XL184) data in
prostate cancer at ASCO GU symposium
Earnings: Biomarin Pharmaceuticals(BMRN_), Acorda Therapeutics(ACOR_)
Feb. 22:
Earnings: Questcor Pharmaceuticals(QCOR_)
Feb 25:
Pfizer and Protalix Therapeutics(PLX_): FDA approval decision date for
Uplyso in Gaucher's disease.
Other potential February events
Idenix Pharmaceuticals(IDIX_): FDA decision on lifting clinical hold on
hepatitis C drugs IDX184 and IDX320.
Amylin Pharmaceuticals(AMLN_), Alkermes, Eli Lilly(LLY_): Start of a
Bydureon Qt study.
Source: Company reports, BioMedTracker.com
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
>To submit a news tip, send an email to: t**[email protected].
1 (共1页)
相关主题
ALIM的新药申请 FDA接收了吗?关于医药股操作,再胡说几句 (转载)
老牛, 觉得ALIM怎么样, 有前途吗?说几个最近(一周到半年)有可能有动作的biotech:
alimBiotech Calendar: 2011 FDA Drug Approvals
ALIM近期走向如何啊肝病生拉月末有event | ANDS| IDIX
【Biotech Event Thread】2009 OctBiotech Calendar: 2011-12 FDA Drug Approvals
生拉AVNRWatch GENZ, SNY approach GENZ for interest of buy out
大家看看这几个公司被买断的可能性怎么样? (转载)Sanofi makes $18.5 billion all-cash offer for Genzyme
Stock Lists on Finviz (转载)中国数据强劲,美股期指劲扬
相关话题的讨论汇总
话题: feb话题: earnings话题: february话题: avnr